NICE draft guidance recommends PCSK9 inhibitors for high risk cardiovascular patients

The National Institute for Health and Care Excellence (NICE), the UK’s cost-effectiveness body, has recommended two new cholesterol-lowering drugs for certain adults with primary hypercholesterolaemia or mixed dyslipidaemia who are at extremely high risk of heart attacks and strokes.…